{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Keros Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"KROS"},"Address":{"label":"Address","value":"99 HAYDEN AVENUE,SUITE 120, BUILDING E SUITE 302, LEXINGTON, Massachusetts, 02421, United States"},"Phone":{"label":"Phone","value":"+1 617 314-6297"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis."},"CompanyUrl":{"label":"Company Url","value":"https://www.kerostx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher Rovaldi","title":"President & Chief Operating Officer"},{"name":"Jasbir S. Seehra","title":"Chairman & Chief Executive Officer"},{"name":"Jennifer Lachey","title":"Senior Vice President-Research"},{"name":"Yung H. Chyung","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}